Why Vitamin K2 (MK-7) Should Be Considered Alongside Calcium and Vitamin D in Bone Health

The Current Standard: Calcium and Vitamin D

Calcium and vitamin D combinations are the cornerstone of NHS bone health prescribing. Common preparations include Calci-D® (1,000 mg calcium + 1,000 IU vitamin D3, once daily) and Adcal-D3® (600 mg calcium + 400 IU vitamin D3 per chewable tablet, typically twice daily). Both support bone mineralisation and address the widespread vitamin D deficiency affecting UK adults, especially in autumn and winter.

Where combination products do not provide sufficient vitamin D, UKHSA and NHS guidance supports prescribing separate colecalciferol (vitamin D3) at 800–2,000 IU daily for patients with osteopenia, osteoporosis, or other high-risk conditions. The safe upper limit for most adults is 4,000 IU per day.

The Missing Link: Vitamin K2 (MK-7)

Calcium and vitamin D supply and help absorb calcium — but neither determines where in the body it ends up. Research interest is growing in the role of Vitamin K2 (MK-7) in directing calcium effectively into bone and away from soft tissues.

Vitamin K2 (MK-7) activates two key proteins:

• Osteocalcin — binds calcium into the bone matrix
• Matrix Gla Protein (MGP) — may inhibit calcium from accumulating in arterial walls

Regulatory recognition: The European Food Safety Authority (EFSA) has accepted a general function health claim for vitamin K and the maintenance of normal bone — recognising it as an evidence-based contributor to skeletal health (EFSA, 2009).

The Evidence Base

Peer-reviewed trials support a role for Vitamin K2 (MK-7) in bone health. Key findings include:

• Bone mineral density (BMD): A three-year, double-blind RCT found 180 μg/day MK-7 significantly slowed age-related BMD decline in healthy postmenopausal women (Knapen et al., 2013). A 2024 systematic review confirmed vitamin K supplementation increased lumbar spine BMD, with the strongest effects in females (Xie et al., 2024).
• Bone microarchitecture: A 12-month RCT found MK-7 preserved trabecular bone structure at the tibia in postmenopausal women with osteopenia (Rønn et al., 2016).
• Vascular biomarkers: A three-year RCT found 180 μg/day MK-7 significantly reduced arterial stiffness (Knapen et al., 2015). A 2023 meta-analysis of 14 RCTs showed a borderline significant effect on coronary artery calcification (Li, Wang and Tu, 2023). A separate RCT found no benefit for aortic valve calcification in men with established stenosis (Diederichsen et al., 2022). Cardiovascular evidence remains mixed.

Current NICE Guidelines

The 2024 UK clinical guideline (NOGG, Gregson et al., 2025) is the current authoritative standard for osteoporosis management in the UK. NICE Clinical Knowledge Summaries (CKS) were last revised in April 2025.

Key recommendations include:

• Calcium and vitamin D supplementation as an adjunct to anti-osteoporosis drug treatment where dietary intake is low or vitamin D insufficiency is a risk
• At least 800 IU vitamin D daily for those with vitamin D insufficiency or risk factors
• Fracture risk assessment using FRAX® or QFracture® tools
• Bisphosphonates, denosumab, or other licensed bone-active therapies as primary pharmacological treatment

Current position: Vitamin K2 (MK-7) is not currently included in NICE or NOGG recommendations. The evidence base, while promising for BMD, is not yet considered sufficient to support routine supplementation in UK clinical practice. NICE is developing updated guidance on osteoporosis management.

Royal Osteoporosis Society Current Guidance

The ROS Further Food Facts and Bones resource acknowledges that vitamin K activates osteocalcin for bone building, and that diets rich in vitamin K are associated with a lower risk of hip fractures (Royal Osteoporosis Society, n.d.).

However, it states: "Evidence on the effects of vitamin K supplements on bone health and strength isn't strong, so currently supplements are not recommended." On vascular protection, studies are described as "inconclusive."

Since this guidance was published, additional clinical evidence has emerged — including the Knapen et al. (2013) three-year RCT, the Huang et al. (2015) meta-analysis of 19 trials, and the Xie et al. (2024) systematic review — which may warrant a review of the current position.

⚠️ Warfarin warning (ROS): Vitamin K has a role in blood clotting. Patients taking warfarin or other vitamin K antagonist anticoagulants must not take vitamin K supplements without first discussing this with their GP or anticoagulation clinic.

Safe Dosing Evidence

Nutrient	Recommended intake	Upper safe limit	Notes
Calcium	700–1,200 mg/day (all sources)	Supplement only if dietary intake < 700 mg/day	Dietary sources preferred; high-dose supplements may cause GI side-effects
Vitamin D3	800–2,000 IU/day (high-risk groups); 400 IU/day general adults (UKHSA)	4,000 IU/day	D3 preferred over D2; daily dosing preferred
Vitamin K2 (MK-7)	180 µg/day (clinical trial dose)	360 µg/day (EFSA)	⚠️ Contraindicated with warfarin — discuss with GP first
Magnesium	270–300 mg/day (UK RNI)	250 mg/day from supplements (EU)	Excess may cause diarrhoea; dietary sources preferred
Protein	1.0–1.2 g/kg/day (older adults)	~2.0 g/kg/day	Distribute across meals for bone and muscle support

A Practical Path Forward

For patients with osteopenia or osteoporosis and multiple risk factors, a comprehensive approach could include:

• An NHS-approved calcium + vitamin D preparation (e.g., Calci-D® 1,000 mg/1,000 IU once daily, or Adcal-D3® 600 mg/400 IU twice daily)
• Vitamin K2 (MK-7) 180 µg/day as an affordable over-the-counter supplement, subject to clinical eligibility and absent contraindications
• Individualised monitoring of vitamin D and calcium levels

Always consult your GP or pharmacist before starting any new supplement, particularly if you take anticoagulants, have kidney impairment, or have hypercalcaemia.

Conclusion

The bone health conversation needs to evolve. While calcium and vitamin D remain essential, Vitamin K2 (MK-7) offers a clinically plausible and evidence-supported complementary role — particularly for bone mineral density and osteocalcin activation. Current NICE and ROS guidance does not recommend routine K2 supplementation, reflecting the need for larger-scale RCTs in non-Japanese populations with hard fracture endpoints.

As the evidence base matures, a review of prescribing guidance would be warranted. In the meantime, where there is no contraindication, Vitamin K2 (MK-7) represents a safe, affordable, and scientifically grounded supplement that deserves greater clinical attention.

⚠️ IMPORTANT MEDICAL DISCLAIMER

The content in this post is for educational and informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your GP or other qualified health provider with any questions about a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read here. Always consult your GP or pharmacist before starting any new supplement, particularly if you are taking warfarin, other anticoagulants, or any prescription medication, or if you have kidney disease, hypercalcaemia, or a history of kidney stones.

---

References

1. Royal Osteoporosis Society (2024) Vitamin D and Bone Health. Available at: https://theros.org.uk/information-and-support/osteoporosis/treatment/vitamin-d-and-bone-health/
2. NHS England (2023) Calcium and Vitamin D (Colecalciferol) Preparations for Adults at Risk of Osteoporosis. North East London ICB. Available at: NEL ICB Guidance (PDF)
3. Right Decisions NHS Scotland (2023) Calcium and Vitamin D Formulary. Available at: https://rightdecisions.scot.nhs.uk
4. Torbay and South Devon NHS (2023) Vitamin D Treatment Pathway. Available at: https://www.torbayandsouthdevon.nhs.uk/uploads/24008.pdf
5. Oxfordshire Joint Formulary (2024) Osteoporosis – Calcium and Vitamin D Preparations. Available at: https://www.oxfordshireformulary.nhs.uk
6. NHS Greater Glasgow and Clyde (2023) Vitamin D and Calcium Supplement Reminder. Available at: https://ggcmedicines.org.uk
7. Knapen, M.H.J., Drummen, N.E., Smit, E., Vermeer, C. and Theuwissen, E. (2013) 'Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women', Osteoporosis International, 24(9), pp. 2499–2507. Available at: https://pubmed.ncbi.nlm.nih.gov/23525894/
8. Wasilewski, G.B., Vervloet, M.G. and Schurgers, L.J. (2019) 'The Bone—Vasculature Axis: Calcium Supplementation and the Role of Vitamin K', Frontiers in Cardiovascular Medicine, 6, p. 6. Available at: https://doi.org/10.3389/fcvm.2019.00006
9. Huang, Z.B., Wan, S.L., Lu, Y.J., Ning, L., Liu, C. and Fan, S.W. (2015) 'Does vitamin K2 play a role in the prevention and treatment of osteoporosis for postmenopausal women: a meta-analysis of randomized controlled trials', Osteoporosis International, 26(3), pp. 1175–1186. Available at: https://pubmed.ncbi.nlm.nih.gov/25516361/
10. Knapen, M.H.J., Braam, L.A.J.L.M., Drummen, N.E., Bekers, O., Hoeks, A.P.G. and Vermeer, C. (2015) 'Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women: a double-blind randomised clinical trial', Thrombosis and Haemostasis, 113(5), pp. 1135–1144. Available at: https://doi.org/10.1160/TH14-08-0675
11. Rønn, S.H., Harsløf, T., Pedersen, S.B. and Langdahl, B.L. (2016) 'Vitamin K2 (menaquinone-7) prevents age-related deterioration of trabecular bone microarchitecture at the tibia in postmenopausal women', European Journal of Endocrinology, 175(6), pp. 541–549. Available at: https://doi.org/10.1530/EJE-16-0498
12. EFSA Panel on Dietetic Products, Nutrition and Allergies (2017) 'Scientific opinion on the safety of vitamin K2 (menaquinone-7)', EFSA Journal, 15(5), p. 4780. Available at: https://doi.org/10.2903/j.efsa.2017.4780
13. Royal Osteoporosis Society (2024) Vitamin K and Bone Health. Available at: https://theros.org.uk/information-and-support/osteoporosis/treatment/vitamin-k-and-bone-health/
14. Institute of Medicine (2011) Dietary Reference Intakes for Calcium and Vitamin D. Washington DC: National Academies Press. Available at: https://www.ncbi.nlm.nih.gov/books/NBK56070/
15. National Institute for Health and Care Excellence (2025) Osteoporosis – Prevention of Fragility Fractures. Clinical Knowledge Summary, last revised April 2025. Available at: https://cks.nice.org.uk/topics/osteoporosis-prevention-of-fragility-fractures/
16. Gregson, C.L., Armstrong, D.J., Avgerinou, C., Cooper, C., Gittoes, N.J.L. and Harvey, N.C. et al. (2025) 'The 2024 UK clinical guideline for the prevention and treatment of osteoporosis', Archives of Osteoporosis, 20(1), p. 119. Available at: https://doi.org/10.1007/s11657-025-01588-3
17. Royal Osteoporosis Society (n.d.) Further Food Facts and Bones. Available at: ROS Further Food Facts (PDF)
18. Xie, C., Gong, J., Zheng, C., Zhang, J., Gao, J., Tian, C., Guo, X., Dai, S. and Gao, T. (2024) 'Effects of vitamin K supplementation on bone mineral density at different sites and bone metabolism in the middle-aged and elderly population', Bone & Joint Research, 13(12), pp. 750–763. Available at: https://doi.org/10.1302/2046-3758.1312.BJR-2024-0053.R1
19. Li, T., Wang, Y. and Tu, W.P. (2023) 'Vitamin K supplementation and vascular calcification: a systematic review and meta-analysis of randomized controlled trials', Frontiers in Nutrition, 10, p. 1115069. Available at: https://doi.org/10.3389/fnut.2023.1115069
20. Diederichsen, A.C.P., Lindholt, J.S., Möller, S., Øvrehus, K.A., Auscher, S., Lambrechtsen, J., Hosbond, S.E., Alan, D.H., Urbonaviciene, G., Becker, S.W., Fredgart, M.H., Hasific, S., Folkestad, L., Gerke, O., Rasmussen, L.M., Møller, J.E., Mickley, H. and Dahl, J.S. (2022) 'Vitamin K2 and D in patients with aortic valve calcification: a randomized double-blinded clinical trial', Circulation, 145(18), pp. 1387–1397. Available at: https://doi.org/10.1161/CIRCULATIONAHA.121.057008
21. European Food Safety Authority (2009) 'Scientific opinion on the substantiation of health claims related to vitamin K and maintenance of bone', EFSA Journal, 7(9), p. 1228. Available at: https://doi.org/10.2903/j.efsa.2009.1228

Calci-D®, Adcal-D3®, and Accrete D3® are registered trademarks of their respective manufacturers. All trademarks are acknowledged.